E Merck To Acquire France's Poly Labo

2 January 1995

Merck AG of Switzerland, the holding company for E Merck of Germany, is acquiring the laboratory supply business group Poly Labo International SA of Strasbourg, France, via its French subsidiary Merck-Clevenot SA. The main operating company is Poly Labo Paul Block & Cie in Strasbourg, which was founded in 1953; Delta Bio is a branch in Brussels, Belgium, and Poly Labo Suisse is a joint venture in Geneva. In 1994, the consolidated sales of the group will amount to over 50 million Swiss francs ($37.5 million). The company has a staff of 85 people, 22 of whom work in the field.

This acquisition is a further step by the Merck AG group to consolidate its leading position in the European laboratory supply business, according to the Swiss company. It provides Merck with access to a market growing at an above-average rate for laboratory consumables and small instruments for use in molecular biological and biotechnological research, in which Poly Labo is a market leader.

Two years ago in France, Merck acquired Prolabo SA, a Paris-based laboratory supply business largely active in the industrial and research segments, particularly in chemicals.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight